AI Article Synopsis
- The study examined how hormone replacement therapy (HRT) affects blood clotting factors, specifically tissue factor (TF) and tissue factor pathway inhibitor (TFPI), in postmenopausal women.
- Researchers looked at 76 healthy women, comparing those on oral or transdermal HRT with a control group not taking HRT, measuring various coagulation parameters.
- Findings showed higher TF and lower TFPI levels in HRT users, suggesting a hypercoagulable state, but no significant changes in other markers indicated a low risk of thrombosis.
Article Abstract
Objective: The influence of hormone replacement therapy (HRT) on hemostasis processes depends on the type of hormone, the combination of doses, the time of taking HRT, and the route of administration (oral, transdermal, implanted). The aim of the current study was to assess some parameters of coagulation, especially tissue factor pathway inhibitor (TFPI) and tissue factor (TF) in postmenopausal women using oral or transdermal HRT.
Methods: The study was conducted on 76 healthy women, including 46 women aged 44-58 years who were taking oral (26) or transdermal (20) HRT, and 30 women aged 44-54 years who did not take HRT as the control group. Plasma concentrations of TF, TFPI, thrombin-antithrombin complex (TAT), and D-dimer were performed by enzyme-linked immunosorbent assay (ELISA). Moreover, the concentration of fibrinogen and activity of protein C were measured by chromogenic and chronometric methods.
Results: We observed a significantly higher concentration of TF and a significantly lower concentration of TFPI in women taking oral and transdermal HRT in comparison with the control group. We also found a significantly lower concentration of fibrinogen in women taking oral HRT vs. the control group. Moreover, no statistically significant changes in concentrations of TAT and D-dimer, or activity of protein C were noted.
Conclusions: In this study, the occurrence of an increased TF concentration simultaneously with a decreased concentration of TFPI in women taking HRT indicates hypercoagulability. No significant modification of TAT or D-dimer occurred, and thus there may not be increased risk of thrombosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3017411 | PMC |
| http://dx.doi.org/10.1631/jzus.B1000106 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Associations of blood pressure with white matter hyperintensities later in life; influence of short-term menopausal hormone therapy.
Menopause
January 2025
From the Department of Radiology, Mayo Clinic, Rochester, MN.
Objective: To assess the association of systolic and diastolic blood pressure (SBP and DBP) in recently menopausal women with white matter hyperintensity (WMH) volume later in life and determine whether short-term menopausal hormone therapy (mHT) modifies these associations.
Methods: Kronos Early Estrogen Prevention Study (KEEPS) was a multicenter, randomized, double-blinded, placebo-controlled 4-year mHT trial (oral conjugated equine estrogens or transdermal 17β-estradiol). KEEPS continuation was an observational follow-up of the participants 10 years after the end of mHT.
UPDATE ON MEDICAL TREATMENT OF ENDOMETRIOSIS: NEW DRUGS OR NEW THERAPEUTIC APPROACHES?
Gynecol Obstet Invest
December 2024
Background: No conceptually new drugs for the safe and successful cure of endometriosis are likely to become available soon. Hormonal modulation of ovarian function and suppression of menstruation remain the pillars of disease control. However, existing drugs may be used following novel modalities to limit the consequences of endometriosis progression.
View Article and Find Full Text PDFDermal penetration of 2-phenoxyethanol in humans: in vivo metabolism and toxicokinetics.
Arch Toxicol
December 2024
Institute and Outpatient Clinic of Occupational, Social and Environmental Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
2-Phenoxyethanol (PhE) is an amphiphilic organic compound frequently used as a broad-spectrum preservative in cosmetic products and other consumer goods. PhE is also used as a biocidal component in occupational settings. A previous volunteer study by our working group following oral exposure to PhE showed that PhE is almost completely taken up into the human body followed by an extensive metabolization and fast urinary elimination.
View Article and Find Full Text PDFEfficacy of transdermal ketoprofen on surgical inflammation in dogs.
Res Vet Sci
December 2024
School of Veterinary Science, The University of Queensland, Gatton, QLD 4343, Australia. Electronic address:
Ketoprofen is a non-steroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation in dogs. Despite having effective analgesic efficacy, prolonged oral administration has been associated with adverse effects. Transdermal delivery of ketoprofen has reduced the incidence of adverse effects in humans and could potentially be used in veterinary clinical medicine.
View Article and Find Full Text PDFIntegrating 3D-printed hydrogels and polymeric nanofibers in a double-layered transdermal patch for the treatment of rheumatoid arthritis.
RSC Adv
December 2024
Nanomedicine Laboratories, Center for Materials Science, Zewail City of Science and Technology 6th of October City Giza Egypt
Patients with rheumatoid arthritis (RA), an inflammatory illness that affects the synovial joints, have a much worse quality of life. Mostly, oral or injectable formulations are used to treat RA, underscoring the critical need for an innovative medication delivery method to enhance therapeutic outcomes and patient compliance. The present study integrated 3D bioprinting and electrospinning technologies to create a unique double-layered transdermal patch (TDDP) for the treatment of RA.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!